81 FR 4628 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 81, Issue 17 (January 27, 2016)
Food and Drug Administration
Federal Register Volume 81, Issue 17 (January 27, 2016)
| Page Range | 4628-4631 | |
| FR Document | 2016-01638 |
[Federal Register Volume 81, Number 17 (Wednesday, January 27, 2016)] [Notices] [Pages 4628-4631] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-01638] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2012-N-0559] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by February 26, 2016. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to [email protected]. All comments should be identified with the OMB control number 0910-0456. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected]. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. PHS Guideline on Infectious Disease Issues in Xenotransplantation OMB Control Number 0910-0456--Extension The statutory authority to collect this information is provided under sections 351 and 361 of the PHS Act (42 U.S.C. 262 and 264) and the provisions of the Federal Food, Drug, and Cosmetic Act that apply to drugs (21 U.S.C. 301 et seq.). The PHS guideline recommends procedures to diminish the risk of transmission of infectious agents to the xenotransplantation product recipient and to the general public. The PHS guideline is intended to address public health issues raised by xenotransplantation, through identification of general principles of prevention and control of infectious diseases associated with xenotransplantation that may pose a hazard to the public health. The collection of information described in this guideline is intended to provide general guidance on the following topics: (1) The development of xenotransplantation clinical protocols; (2) the preparation of submissions to FDA; and (3) the conduct of xenotransplantation clinical trials. Also, the collection of information will help ensure that the sponsor maintains important information in a cross-referenced system that links the relevant records of the xenotransplantation product recipient, xenotransplantation product, source animal(s), animal procurement center, and significant nosocomial exposures. The PHS guideline describes an occupational health service program for the protection of health care workers involved in xenotransplantation procedures, caring for xenotransplantation product recipients, and performing associated laboratory testing. The PHS guideline is intended to protect the public health and to help ensure the safety of using xenotransplantation products in humans by preventing the introduction, transmission, and spread of infectious diseases associated with xenotransplantation. The PHS guideline also recommends that certain specimens and records be maintained for 50 years beyond the date of the xenotransplantation. These include: (1) Records linking each xenotransplantation product recipient with relevant health records of the source animal, herd or colony, and the specific organ, tissue, or cell type included in or used in the manufacture of the product (section 3.2.7.1); (2) aliquots of serum samples from randomly selected animal and specific disease investigations (section 3.4.3.1); (3) source animal biological specimens designated for PHS use (section 3.7.1); animal health records (section 3.7.2), including necropsy results (section 3.6.4); and (4) recipients' biological specimens (section 4.1.2). The retention period is intended to assist health care practitioners and officials in surveillance and in tracking the source of an infection, disease, or illness that might emerge in the recipient, the source animal, or the animal herd or colony after a xenotransplantation. The recommendation for maintaining records for 50 years is based on clinical experience with several human viruses that have presented problems in human to human transplantation and are therefore thought to share certain characteristics with viruses that may pose potential risks in xenotransplantation. These characteristics include long latency periods and the ability to establish persistent infections. Several also share the possibility of transmission among individuals through intimate contact with human body fluids. Human immunodeficiency virus (HIV) and human T-lymphotropic virus are human retroviruses. Retroviruses contain ribonucleic acid that is reverse-transcribed into deoxyribonucleic acid (DNA) using an enzyme provided by the virus and the human cell machinery. That viral DNA can then be integrated into the human cellular DNA. Both viruses establish persistent infections and have long latency periods before the onset of disease; 10 years and 40 to 60 years, respectively. The human hepatitis viruses are not retroviruses, but several share with HIV the characteristic that they can be transmitted through body [[Page 4629]] fluids, can establish persistent infections, and have long latency periods, e.g., approximately 30 years for hepatitis C. In addition, the PHS guideline recommends that a record system be developed that allows easy, accurate, and rapid linkage of information among the specimen archive, the recipient's medical records, and the records of the source animal for 50 years. The development of such a record system is a one-time burden. Such a system is intended to cross- reference and locate relevant records of recipients, products, source animals, animal procurement centers, and nosocomial exposures. Respondents to this collection of information are the sponsors of clinical studies of investigational xenotransplantation products under investigational new drug applications (INDs) and xenotransplantation product procurement centers, referred to as source animal facilities. There are an estimated three respondents who are sponsors of INDs that include protocols for xenotransplantation in humans and five clinical centers doing xenotransplantation procedures. Other respondents for this collection of information are an estimated four source animal facilities which provide source xenotransplantation product material to sponsors for use in human xenotransplantation procedures. These four source animal facilities keep medical records of the herds/colonies as well as the medical records of the individual source animal(s). The burden estimates are based on FDA's records of xenotransplantation- related INDs and estimates of time required to complete the various reporting, recordkeeping, and third-party disclosure tasks described in the PHS guideline. FDA is requesting an extension of OMB approval for the following reporting, recordkeeping, and third-party disclosure recommendations in the PHS guideline: Table 1--Reporting Recommendations ------------------------------------------------------------------------ PHS guideline section Description ------------------------------------------------------------------------ 3.2.7.2.................................... Notify sponsor or FDA of new archive site when the source animal facility or sponsor ceases operations. ------------------------------------------------------------------------ Table 2--Recordkeeping Recommendations ------------------------------------------------------------------------ PHS guideline section Description ------------------------------------------------------------------------ 3.2.7...................................... Establish records linking each xenotransplantation product recipient with relevant records. 4.3........................................ Sponsor to maintain cross- referenced system that links all relevant records (recipient, product, source animal, animal procurement center, and nosocomial exposures). 3.4.2...................................... Document results of monitoring program used to detect introduction of infectious agents which may not be apparent clinically. 3.4.3.2.................................... Document full necropsy investigations including evaluation for infectious etiologies. 3.5.1...................................... Justify shortening a source animal's quarantine period of 3 weeks prior to xenotransplantation product procurement. 3.5.2...................................... Document absence of infectious agent in xenotransplantation product if its presence elsewhere in source animal does not preclude using it. 3.5.4...................................... Add summary of individual source animal record to permanent medical record of the xenotransplantation product recipient. 3.6.4...................................... Document complete necropsy results on source animals (50-year record retention). 3.7........................................ Link xenotransplantation product recipients to individual source animal records and archived biologic specimens. 4.2.3.2.................................... Record baseline sera of xenotransplantation health care workers and specific nosocomial exposure. 4.2.3.3 and 4.3.2.......................... Keep a log of health care workers' significant nosocomial exposure(s). 4.3.1...................................... Document each xenotransplant procedure. 5.2........................................ Document location and nature of archived PHS specimens in health care records of xenotransplantation product recipient and source animal. ------------------------------------------------------------------------ Table 3--Disclosure Recommendations ------------------------------------------------------------------------ PHS guideline section Description ------------------------------------------------------------------------ 3.2.7.2.................................... Notify sponsor or FDA of new archive site when the source animal facility or sponsor ceases operations. 3.4........................................ Standard operating procedures (SOPs) of source animal facility should be available to review bodies. 3.5.1...................................... Include increased infectious risk in informed consent if source animal quarantine period of 3 weeks is shortened. 3.5.4...................................... Sponsor to make linked records described in section 3.2.7 available for review. 3.5.5...................................... Source animal facility to notify clinical center when infectious agent is identified in source animal or herd after xenotransplantation product procurement. ------------------------------------------------------------------------ In the Federal Register of October 5, 2015 (80 FR 60153), FDA published a 60-day notice requesting public comment on the proposed collection of information. FDA received one comment from the public. The comment was supportive of the extended recordkeeping requirements in case it would be necessary to track the source of any long-term developing infections as result of xenotransplantation. FDA estimates the burden for this collection of information as follows: [[Page 4630]] Table 4--Estimated Annual Reporting Burden \1\ -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of PHS guideline section Number of responses per Total annual Average burden per response Total hours respondents respondent responses -------------------------------------------------------------------------------------------------------------------------------------------------------- 3.2.7.2 \2\.............................. 1 1 1 0.5 (30 minutes)............................. 0.5 -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. \2\ FDA is using 1 animal facility or sponsor for estimation purposes. Table 5--Estimated Annual Recordkeeping Burden \1\ -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of PHS guideline section Number of records per Total annual Average burden per recordkeeping Total hours recordkeepers recordkeeper records -------------------------------------------------------------------------------------------------------------------------------------------------------- 3.2.7 \2\................................ 1 1 1 16........................................... 16 4.3 \3\.................................. 3 1 3 0.75 (45 minutes)............................ 2.25 3.4.2 \4\................................ 3 10.67 32 0.25 (15 minutes)............................ 8 3.4.3.2 \5\.............................. 3 2.67 8 0.25 (15 minutes)............................ 2 3.5.1 \6\................................ 3 0.33 1 0.50 (30 minutes)............................ 0.5 3.5.2 \6\................................ 3 0.33 1 0.25 (15 minutes)............................ 0.25 3.5.4.................................... 3 1 3 0.17 (10 minutes)............................ 0.51 3.6.4 \7\................................ 3 2.67 8 0.25 (15 minutes)............................ 2 3.7 \7\.................................. 4 2 8 0.08 (5 minutes)............................. 0.64 4.2.3.2 \8\.............................. 5 25 125 0.17 (10 minutes)............................ 21.25 4.2.3.2 \6\.............................. 5 0.20 1 0.17 (10 minutes)............................ 0.17 4.2.3.3 and 4.3.2 \6\.................... 5 0.20 1 0.17 (10 minutes)............................ 0.17 4.3.1.................................... 3 1 3 0.25 (15 minutes)............................ 0.75 5.2 \9\.................................. 3 4 12 0.08 (5 minutes)............................. 0.96 -------------------------------------------------------------------------------------------------------------- Total................................ .............. .............. .............. ............................................. 55.45 -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. \2\ A one-time burden for new respondents to set up a recordkeeping system linking all relevant records. FDA is using one new sponsor for estimation purposes. \3\ FDA estimates there is minimal recordkeeping burden associated with maintaining the record system. \4\ Monitoring for sentinel animals (subset representative of herd) plus all source animals. There are approximately 6 sentinel animals per herd x 1 herd per facility x 4 facilities = 24 sentinel animals. There are approximately 8 source animals per year (see footnote 7 of this table); 24 + 8 = 32 monitoring records to document. \5\ Necropsy for animal deaths of unknown cause estimated to be approximately 2 per herd per year x 1 herd per facility x 4 facilities = 8. \6\ Has not occurred in the past 3 years and is expected to continue to be a rare occurrence. \7\ On average 2 source animals are used for preparing xenotransplantation product material for one recipient. The average number of source animals is 2 source animals per recipient x 4 recipients annually = 8 source animals per year. (See footnote 5 of table 6.) \8\ FDA estimates there are 5 clinical centers doing xenotransplantation procedures x approximately 25 health care workers involved per center = 125 health care workers. \9\ Eight source animal records + 4 recipient records = 12 total records. Table 6--Estimated Annual Third-Party Disclosure Burden -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of Number of disclosures Total annual PHS guideline section respondents per disclosures Average burden per disclosure Total hours respondent -------------------------------------------------------------------------------------------------------------------------------------------------------- 3.2.7.2 \2\.............................. 1 1 1 0.5 (30 minutes)............................. 0.5 3.4 \3\.................................. 4 0.25 1 0.08 (5 minutes)............................. 0.08 3.5.1 \4\................................ 4 0.25 1 0.25 (15 minutes)............................ 0.25 3.5.4 \5\................................ 4 1 4 0.5 (30 minutes)............................. 2 3.5.5 \4\................................ 4 0.25 1 0.25 (15 minutes)............................ 0.25 -------------------------------------------------------------------------------------------------------------- Total................................ .............. .............. .............. ............................................. 3.08 -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. \2\ FDA is using one animal facility or sponsor for estimation purposes. \3\ FDA's records indicate that an average of 1 IND is expected to be submitted per year. \4\ To our knowledge, has not occurred in the past 3 years and is expected to continue to be a rare occurrence. \5\ Based on an estimate of 12 patients treated over a 3-year period, the average number of xenotransplantation product recipients per year is estimated to be 4. Because of the potential risk for cross-species transmission of pathogenic persistent virus, the guideline recommends that health records be retained for 50 years. Since these records are medical records, the retention of such records for up to 50 years is not information subject to the PRA (5 CFR 1320.3(h)(5)). Also, because of the limited number of clinical studies with small patient populations, the number of records is expected to be insignificant at this time. Information collections in this guideline not included in tables 1 through 6 can be found under existing regulations and approved under the [[Page 4631]] OMB control numbers as follows: (1) ``Current Good Manufacturing Practice for Finished Pharmaceuticals,'' 21 CFR 211.1 through 211.208, approved under OMB control number 0910-0139; (2) ``Investigational New Drug Application,'' 21 CFR 312.1 through 312.160, approved under OMB control number 0910-0014; and (3) information included in a biologics license application, 21 CFR 601.2, approved under OMB control number 0910-0338. (Although it is possible that a xenotransplantation product may not be regulated as a biological product (e.g., it may be regulated as a medical device), FDA believes, based on its knowledge and experience with xenotransplantation, that any xenotransplantation product subject to FDA regulation within the next 3 years will most likely be regulated as a biological product.) However, FDA recognized that some of the information collections go beyond approved collections; assessments for these burdens are included in tables 1 through 6. In table 7, FDA identifies those collections of information activities that are already encompassed by existing regulations or are consistent with voluntary standards which reflect industry's usual and customary business practice. Table 7--Collection of Information Required by Current Regulations and Standards ---------------------------------------------------------------------------------------------------------------- Description of collection of 21 CFR section (unless PHS guideline section information activity otherwise stated) ---------------------------------------------------------------------------------------------------------------- 2.2.1........................................... Document offsite collaborations.. 312.52. 2.5............................................. Sponsor ensures counseling 312.62(c). patient + family + contacts. 3.1.1 and 3.1.6................................. Document well-characterized 312.23(a)(7)(a) and 211.84. health history and lineage of source animals. 3.1.8........................................... Registration with and import 42 CFR 71.53. permit from the Centers for Disease Control and Prevention. 3.2.2........................................... Document collaboration with 312.52. accredited microbiology labs. 3.2.3........................................... Procedures to ensure the humane 9 CFR parts 1, 2, and 3 and care of animals. PHS Policy.\1\ 3.2.4........................................... Procedures consistent for AAALAC International Rules accreditation by the Association of Accreditation \2\ and for Assessment and Accreditation NRC Guide.\3\ of Laboratory Animal Care International (AAALAC International) and consistent with the National Research Council's (NRC) Guide. 3.2.5, 3.4, and 3.4.1........................... Herd health maintenance and 211.100 and 211.122. surveillance to be documented, available, and in accordance with documented procedures; record standard veterinary care. 3.2.6........................................... Animal facility SOPs............. PHS Policy.\1\ 3.3.3........................................... Validate assay methods........... 211.160(a). 3.6.1........................................... Procurement and processing of 211.100 and 211.122. xenografts using documented aseptic conditions. 3.6.2........................................... Develop, implement, and enforce 211.84(d) and 211.122(c). SOPs for procurement and screening processes. 3.6.4........................................... Communicate to FDA animal 312.32(c). necropsy findings pertinent to health of recipient. 3.7.1........................................... PHS specimens to be linked to 312.23(a)(6). health records; provide to FDA justification for types of tissues, cells, and plasma, and quantities of plasma and leukocytes collected. 4.1.1........................................... Surveillance of xenotransplant 312.23(a)(6)(iii)(f) and recipient; sponsor ensures (g), and 312.62(b) and documentation of surveillance (c). program life-long (justify >2 yrs.); investigator case histories (2 yrs. after investigation is discontinued). 4.1.2........................................... Sponsor to justify amount and 211.122. type of reserve samples. 4.1.2.2......................................... System for prompt retrieval of 312.57(a). PHS specimens and linkage to medical records (recipient and source animal). 4.1.2.3......................................... Notify FDA of a clinical episode 312.32. potentially representing a xenogeneic infection. 4.2.2.1......................................... Document collaborations (transfer 312.52. of obligation). 4.2.3.1......................................... Develop educational materials 312.50. (sponsor provides investigators with information needed to conduct investigation properly). 4.3............................................. Sponsor to keep records of 312.57 and 312.62(b). receipt, shipment, and disposition of investigative drug; investigator to keep records of case histories. ---------------------------------------------------------------------------------------------------------------- \1\ The ``Public Health Service Policy on Humane Care and Use of Laboratory Animals'' (http://www.grants.nih.gov/grants/olaw/references/phspol.htm). \2\ AAALAC International Rules of Accreditation (http://www.aaalac.org/accreditation/rules.cfm). \3\ The NRC's ``Guide for the Care and Use of Laboratory Animals.'' Dated: January 22, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016-01638 Filed 1-26-16; 8:45 am] BILLING CODE 4164-01-P
![4628 Federal Register / Vol. 81, No. 17 / Wednesday, January 27, 2016 / Notices
may request; and (2) provide advice to OMB recommends that written procedures, caring for
the President concerning the following comments be faxed to the Office of xenotransplantation product recipients,
for people with intellectual disabilities: Information and Regulatory Affairs, and performing associated laboratory
(A) Expansion of educational OMB, Attn: FDA Desk Officer, FAX: testing. The PHS guideline is intended
opportunities; (B) promotion of 202–395–7285, or emailed to oira_ to protect the public health and to help
homeownership; (C) assurance of submission@omb.eop.gov. All ensure the safety of using
workplace integration; (D) improvement comments should be identified with the xenotransplantation products in
of transportation options; (E) expansion OMB control number 0910–0456. Also humans by preventing the introduction,
of full access to community living; and include the FDA docket number found transmission, and spread of infectious
(F) increasing access to assistive and in brackets in the heading of this diseases associated with
universally designed technologies. document. xenotransplantation.
Agenda: The Committee Members The PHS guideline also recommends
FOR FURTHER INFORMATION CONTACT: FDA that certain specimens and records be
will discuss preparation of the PCPID PRA Staff, Office of Operations, Food
2016 Report to the President, including maintained for 50 years beyond the date
and Drug Administration, 8455 of the xenotransplantation. These
its contents and format, and related data Colesville Rd., COLE–14526, Silver
collection and analysis required to include: (1) Records linking each
Spring, MD 20993–0002, PRAStaff@ xenotransplantation product recipient
complete the writing of the Report in fda.hhs.gov.
the following focus areas: with relevant health records of the
Family engagement early on in the SUPPLEMENTARY INFORMATION: In source animal, herd or colony, and the
process to support high expectations for compliance with 44 U.S.C. 3507, FDA specific organ, tissue, or cell type
students with disabilities. has submitted the following proposed included in or used in the manufacture
Federal policies and enforcement collection of information to OMB for of the product (section 3.2.7.1); (2)
strategies to end segregation in schools review and clearance. aliquots of serum samples from
and other aspects of community living randomly selected animal and specific
PHS Guideline on Infectious Disease disease investigations (section 3.4.3.1);
beyond graduation. Issues in Xenotransplantation
Transition as a critical area for (3) source animal biological specimens
pathways to higher education and career OMB Control Number 0910–0456— designated for PHS use (section 3.7.1);
development. Extension animal health records (section 3.7.2),
Self-determination/Supported including necropsy results (section
The statutory authority to collect this 3.6.4); and (4) recipients’ biological
decision-making from early childhood information is provided under sections
throughout the individual’s lifespan. specimens (section 4.1.2). The retention
351 and 361 of the PHS Act (42 U.S.C. period is intended to assist health care
Dated: January 14, 2016. 262 and 264) and the provisions of the practitioners and officials in
Aaron Bishop, Federal Food, Drug, and Cosmetic Act surveillance and in tracking the source
Commissioner, Administration on that apply to drugs (21 U.S.C. 301 et of an infection, disease, or illness that
Disabilities. seq.). The PHS guideline recommends might emerge in the recipient, the
[FR Doc. 2016–01586 Filed 1–26–16; 8:45 am] procedures to diminish the risk of source animal, or the animal herd or
BILLING CODE 4154–01–P
transmission of infectious agents to the colony after a xenotransplantation.
xenotransplantation product recipient The recommendation for maintaining
and to the general public. The PHS records for 50 years is based on clinical
DEPARTMENT OF HEALTH AND guideline is intended to address public experience with several human viruses
HUMAN SERVICES health issues raised by that have presented problems in human
xenotransplantation, through to human transplantation and are
Food and Drug Administration identification of general principles of therefore thought to share certain
[Docket No. FDA–2012–N–0559] prevention and control of infectious characteristics with viruses that may
diseases associated with pose potential risks in
Agency Information Collection xenotransplantation that may pose a xenotransplantation. These
Activities; Submission for Office of hazard to the public health. The characteristics include long latency
Management and Budget Review; collection of information described in periods and the ability to establish
Comment Request; Public Health this guideline is intended to provide persistent infections. Several also share
Service Guideline on Infectious general guidance on the following the possibility of transmission among
Disease Issues in Xenotransplantation topics: (1) The development of individuals through intimate contact
xenotransplantation clinical protocols; with human body fluids. Human
AGENCY: Food and Drug Administration, (2) the preparation of submissions to immunodeficiency virus (HIV) and
HHS. FDA; and (3) the conduct of human T-lymphotropic virus are human
ACTION: Notice. xenotransplantation clinical trials. Also, retroviruses. Retroviruses contain
the collection of information will help ribonucleic acid that is reverse-
SUMMARY: The Food and Drug ensure that the sponsor maintains transcribed into deoxyribonucleic acid
Administration (FDA) is announcing important information in a cross- (DNA) using an enzyme provided by the
that a proposed collection of referenced system that links the relevant virus and the human cell machinery.
information has been submitted to the records of the xenotransplantation That viral DNA can then be integrated
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Office of Management and Budget product recipient, xenotransplantation into the human cellular DNA. Both
(OMB) for review and clearance under product, source animal(s), animal viruses establish persistent infections
the Paperwork Reduction Act of 1995. procurement center, and significant and have long latency periods before the
DATES: Fax written comments on the nosocomial exposures. The PHS onset of disease; 10 years and 40 to 60
collection of information by February guideline describes an occupational years, respectively. The human hepatitis
26, 2016. health service program for the viruses are not retroviruses, but several
ADDRESSES: To ensure that comments on protection of health care workers share with HIV the characteristic that
the information collection are received, involved in xenotransplantation they can be transmitted through body
VerDate Sep<11>2014 19:41 Jan 26, 2016 Jkt 238001 PO 00000 Frm 00021 Fmt 4703 Sfmt 4703 E:\FR\FM\27JAN1.SGM 27JAN1](https://thefederalregister.org/doc/81_FR_4645/page/1.svg)
![Federal Register / Vol. 81, No. 17 / Wednesday, January 27, 2016 / Notices 4631
OMB control numbers as follows: (1) (Although it is possible that a collections go beyond approved
‘‘Current Good Manufacturing Practice xenotransplantation product may not be collections; assessments for these
for Finished Pharmaceuticals,’’ 21 CFR regulated as a biological product (e.g., it burdens are included in tables 1 through
211.1 through 211.208, approved under may be regulated as a medical device), 6.
OMB control number 0910–0139; (2) FDA believes, based on its knowledge
In table 7, FDA identifies those
‘‘Investigational New Drug and experience with
collections of information activities that
Application,’’ 21 CFR 312.1 through xenotransplantation, that any
312.160, approved under OMB control xenotransplantation product subject to are already encompassed by existing
number 0910–0014; and (3) information FDA regulation within the next 3 years regulations or are consistent with
included in a biologics license will most likely be regulated as a voluntary standards which reflect
application, 21 CFR 601.2, approved biological product.) However, FDA industry’s usual and customary business
under OMB control number 0910–0338. recognized that some of the information practice.
TABLE 7—COLLECTION OF INFORMATION REQUIRED BY CURRENT REGULATIONS AND STANDARDS
21 CFR section
PHS guideline section Description of collection of information activity (unless otherwise stated)
2.2.1 ....................................... Document offsite collaborations ................................................................... 312.52.
2.5 .......................................... Sponsor ensures counseling patient + family + contacts ............................ 312.62(c).
3.1.1 and 3.1.6 ....................... Document well-characterized health history and lineage of source ani- 312.23(a)(7)(a) and 211.84.
mals.
3.1.8 ....................................... Registration with and import permit from the Centers for Disease Control 42 CFR 71.53.
and Prevention.
3.2.2 ....................................... Document collaboration with accredited microbiology labs ......................... 312.52.
3.2.3 ....................................... Procedures to ensure the humane care of animals .................................... 9 CFR parts 1, 2, and 3 and PHS
Policy.1
3.2.4 ....................................... Procedures consistent for accreditation by the Association for Assess- AAALAC International Rules of Ac-
ment and Accreditation of Laboratory Animal Care International creditation 2 and NRC Guide.3
(AAALAC International) and consistent with the National Research
Council’s (NRC) Guide.
3.2.5, 3.4, and 3.4.1 .............. Herd health maintenance and surveillance to be documented, available, 211.100 and 211.122.
and in accordance with documented procedures; record standard vet-
erinary care.
3.2.6 ....................................... Animal facility SOPs .................................................................................... PHS Policy.1
3.3.3 ....................................... Validate assay methods ............................................................................... 211.160(a).
3.6.1 ....................................... Procurement and processing of xenografts using documented aseptic 211.100 and 211.122.
conditions.
3.6.2 ....................................... Develop, implement, and enforce SOPs for procurement and screening 211.84(d) and 211.122(c).
processes.
3.6.4 ....................................... Communicate to FDA animal necropsy findings pertinent to health of re- 312.32(c).
cipient.
3.7.1 ....................................... PHS specimens to be linked to health records; provide to FDA justifica- 312.23(a)(6).
tion for types of tissues, cells, and plasma, and quantities of plasma
and leukocytes collected.
4.1.1 ....................................... Surveillance of xenotransplant recipient; sponsor ensures documentation 312.23(a)(6)(iii)(f) and (g), and
of surveillance program life-long (justify >2 yrs.); investigator case his- 312.62(b) and (c).
tories (2 yrs. after investigation is discontinued).
4.1.2 ....................................... Sponsor to justify amount and type of reserve samples ............................. 211.122.
4.1.2.2 .................................... System for prompt retrieval of PHS specimens and linkage to medical 312.57(a).
records (recipient and source animal).
4.1.2.3 .................................... Notify FDA of a clinical episode potentially representing a xenogeneic in- 312.32.
fection.
4.2.2.1 .................................... Document collaborations (transfer of obligation) ......................................... 312.52.
4.2.3.1 .................................... Develop educational materials (sponsor provides investigators with infor- 312.50.
mation needed to conduct investigation properly).
4.3 .......................................... Sponsor to keep records of receipt, shipment, and disposition of inves- 312.57 and 312.62(b).
tigative drug; investigator to keep records of case histories.
1 The ‘‘Public Health Service Policy on Humane Care and Use of Laboratory Animals’’ (http://www.grants.nih.gov/grants/olaw/references/
phspol.htm).
2 AAALAC International Rules of Accreditation (http://www.aaalac.org/accreditation/rules.cfm).
3 The NRC’s ‘‘Guide for the Care and Use of Laboratory Animals.’’
Dated: January 22, 2016.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–01638 Filed 1–26–16; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014 19:41 Jan 26, 2016 Jkt 238001 PO 00000 Frm 00024 Fmt 4703 Sfmt 9990 E:\FR\FM\27JAN1.SGM 27JAN1](https://thefederalregister.org/doc/81_FR_4645/page/4.svg)
Document Created: 2018-02-02 12:40:11
Document Modified: 2018-02-02 12:40:11
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Fax written comments on the collection of information by February 26, 2016. | |
| Contact | FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected] | |
| FR Citation | 81 FR 4628 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR